|
|
PVCT Provectus Biopharmaceuticals
|
|
||
BLOOD TEST MONITORING OF TREATMENT: pembrolizumab single-agent treatment monitored with ctDNA blood test I had posted on IV about the RGCC blood test for CTC's (circulating tumor cells) which all cancer patients are believe to have, and can/must/should test & treat (even after immunotherapy treatments) to eliminate, or decrease. Two RGCC blood test websites are here for your friends and family: Today I learn of a new (to me) ctDNA blood test, (to monitor tx success, recurrence and or prevention) by the company Natera. Under "Ongoing Studies" heading: At Princess Margaret Cancer Center I see Natera test being used to monitor single-agent Pembrolizumab treatment. It is believed some blood tests are likely to be even more helpful in monitoring -------than waiting for an expensive, and sometimes not covered by insurance, and or more invasive, Pet-ct scan or image. NOTED: not all blood biopsies are created equal. The above RGCC blood test has zero to do with a physical biopsy, and does NOT require the decreasing in desire, physical biopsy. Looks like this ctDNA test, is possibly and presently connected, to getting a physical biopsy . Unsure. What I do know is: People, as a whole, are less interested in getting physical biopsies, than they were. People are more willing to seek out blood test biopsies, such as RGCC test. Excerpt from this page:
|
return to message board, top of board |